Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726165 | 1.00 | GLS (0.40) | GLSGLANPSR1PTPN1BACE1 | |
| SCHEMBL9196022 | 1.00 | GLS (0.40) | GLSGLANPSR1PTPN1BACE1 | |
| SCHEMBL2158180 | 0.85 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL184053 | 0.85 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL184052 | 0.85 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL12372230 | 0.80 | GLS (0.38) | GLSGLANPSR1 | |
| SCHEMBL21726164 | 0.80 | GLS (0.38) | GLSGLANPSR1 | |
| SCHEMBL264858 | 0.80 | GLS (0.38) | GLSGLANPSR1 | |
| SCHEMBL1005092 | 0.78 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL200462 | 0.78 | GLS (0.47) | GLSBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10561661-B2 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10561661-B2 | Purine derivative compounds for medical use | MSR1, TPMT, M6PR | GLS 617/4885GLA 3324/4885NPSR1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.